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Objective: To evaluate patients’ preferences for various attributes of insulin treatment, includ-
ing route of insulin delivery.
Methods: We used a discrete choice experiment (DCE) to quantify patients’ preferences. The 
attributes (and levels) included in the DCE questionnaire were: glucose control, frequency of 
hypoglycemic events, weight gain, route of administration for the long-acting and the short-
acting insulin, and out-of-pocket cost. Data were analyzed using conditional logit regression 
and segmented models were also developed to evaluate differences in preferences between 
subgroups.
Results: Two hundred and seventy-four questionnaires were completed. The mean age (SD) 
of participants was 56.7 (12.9) years. Forty-nine percent of participants were insulin users, 
and 17% had type 1 diabetes. Overall, patients’ ideal insulin treatment would provide better 
glucose control, result in fewer adverse reactions, have the lowest cost, and be administered 
orally. Overall, there was a strong positive preference for better glucose control relative to the 
other attributes. Segmented analyses by insulin use and type of diabetes suggest that there may 
be an important psychosocial barrier to initiating insulin therapy but that patients tend to adjust 
to subcutaneous administration once they initiate therapy.
Conclusions: This study illustrates the importance that patients with diabetes place on glucose 
control and how preferences for insulin therapy differ between subgroups. Specifically, efforts 
need to be made to overcome the psychosocial barriers to initiating insulin therapy which may 
lead to improved control through improved treatment acceptance and ultimately improve patients’ 
quality of life and reduce the economic burden of the disease.
Keywords: insulin therapy, patients’ preferences, diabetes mellitus, discrete choice 
experiment (DCE)
Introduction
Approximately 5% of adult Canadians have diabetes and it is suggested that this 
prevalence1 may continue to increase. Many patients who could benefit from insulin 
therapy are either not using subcutaneous insulin at all, or are noncompliant.2 Lack 
of diabetes education, inconvenience of repeated daily injections, fear of needles, 
injection-related anxiety, denial, and feeling that the disease has progressed are often 
identified as major barriers to initiating insulin therapy.3
It is conceivable that alternative routes of insulin delivery systems may become a 
clinical reality in the future.4 Two of the most clinically viable routes of delivery that Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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have the potential to greatly improve patients’ compliance 
are oral and pulmonary (ie, inhaled) insulin administration.
The most promising oral insulin to date is hexyl-insulin-
monoconjugate-2 (HIM-2), a recombinant insulin that has 
alterations in its physio-chemical characteristics such that it 
resists enzymatic degradation and facilitates gastrointesintal 
absorption. Ongoing phase I and II clinical trials suggest that 
it has an acceptable glucose-lowering effect. In addition, the 
delivery of oral HIM-2 to the liver through the portal circu-
lation, thereby mimicking the physiological route of insulin 
secretion, may improve control of glucose excursions and 
avoidance of peripheral hyperinsulinemia.5
Pulmonary delivery of insulin is feasible given the large 
surface area and high permeability of the lungs where insu-
lin can be effectively absorbed via the pulmonary alveoli.6 
However, Exubera® (Pfizer), approved for use in 2006 as the 
first available inhaled alternative to injectable insulin, was 
removed from the market less than 2 years later because of a 
limited uptake which may have been related to the cumber-
some delivery system, safety concerns, and cost.7 Regardless, 
attempts to overcome these problems have been made by 
other companies that are developing their own versions of 
inhaled insulin,8 and promising results on patients’ accep-
tance are beginning to emerge. Eliminating injections and 
providing a more physiologically similar insulin secretory 
profile may allow for more intensive insulin delivery that will 
improve glycemic control and reduce complications, while 
enchancing patient compliance.4
Because diabetes is a disease in which a large manage-
ment component is based on a patients’ ability to provide 
their own daily care, for diabetes care to succeed patients 
must be able to make decisions about how they will live with 
their illness.9 Therefore, for health care providers to success-
fully facilitate patients’ treatment acceptance, which in turn 
may lead to greater treatment effectiveness, lower burden of 
disease, and better patient outcomes, they need to consider 
what patients want to incorporate into their decisions for 
diabetes management.10
Despite newer approaches to insulin administration 
and diabetes management on the horizon, there is a paucity 
of information on how patients might “value” alternative, 
noninjectable insulin. Therefore, finding the insulin-delivery 
system and the attributes of insulin therapy that patients 
prefer may lead to improved control through improved 
treatment acceptance, and ultimately reduce the financial 
burden of the disease and improve patients’ quality of 
life. In this context, the objectives of this study were to 
determine patients’ preferences for different attributes of 
insulin therapy and to   determine the value that patients with 
type 1 and type 2 diabetes place on these attributes using a 
discrete choice experiment (DCE). In addition, differences 
in preferences for treatment attributes between predefined 
subgroups, such as type of diabetes and insulin use, were 
also investigated.
Patients and methods
Dce
One of the most effective and widely used techniques to 
evaluate patients’ preferences in the health care domain is 
the DCE, a stated preference technique that has evolved from 
conjoint analysis, and is consistent with economic theory. 
Conjoint analysis is designed to resemble real life, every-
day choices between goods or services with well-defined 
but varying attributes and costs.11 In a DCE questionnaire, 
participants are faced with choices between hypothetical, 
but realistic scenarios comprising different attributes and 
levels that are germane to the decision they are making. 
By asking respondents to make choices between these 
hypothetical scenarios, they are forced to make trade-offs, 
thereby revealing their preferences. By understanding how 
patients choose between treatment options in response to 
changes in the attribute levels, we can estimate the poten-
tial impact that each level of each attribute has on overall 
treatment preference, and the overall preferences for any 
combination of attributes and levels, even if the technology 
is not yet available. In this context, although hypothetical, 
realistic scenarios of potential insulin delivery systems that 
are conceivable of being released were used to design the 
DCE questionnaire.
study design and patients
We performed a cross-sectional study of 378 patients with 
established physician-diagnosed diabetes. Participants were 
eligible for enrolment if they were 18 years of age or older, 
had physician-diagnosed type 1 or type 2 diabetes, were 
using oral hypoglycemic agents and/or insulin, were fluent 
in both reading and writing English, and were able to provide 
informed consent. Participants were recruited through the 
diabetes education clinics at Vancouver General Hospital 
and St Paul’s Hospital in Vancouver, Canada.12
Ethics approval was obtained from Vancouver General 
Hospital, Providence Health Care, and the University of 
British Columbia Behavioral Research Ethics Boards. All 
patients were required to provide informed consent prior to 
enrolling in the study and each participant was remunerated 
C$20 for their time, travel, and parking.Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
435
Patients’ preferences for insulin therapy: a Dce study
Demographics, socioeconomic status,  
and diabetes medication use
Each patient was asked to provide sociodemographic and 
treatment data using a diabetes assessment questionnaire 
which has been designed previously for use in asthma and 
rheumatoid arthritis studies.13,14 Socioeconomic status was 
measured based on education completed and annual house-
hold income. Diabetes history was collected based on type of 
diabetes, insulin status, date of diagnosis, and current use of 
diabetes medication. Diabetes control was measured based on 
patients’ most recent HbA1c levels. Number of hypoglycemic 
events (per month) and self-assessed diabetes control were 
also collected.
Dce questionnaire development
To develop the DCE questionnaire, we completed a qualita-
tive descriptive study using individual interviews and focus 
group techniques to identify the most important attributes of 
insulin therapy from the perspective of patients with diabe-
tes. Two focus groups (4 participants each) and 7 individual 
interviews were conducted. The sample included both men 
and women who attended the diabetes education clinic at 
St Paul’s Hospital in Vancouver, B.C. Interviews typically 
lasted 30 to 50 minutes and all interviews were audio recorded, 
transcribed, and analyzed. Both insulin naïve and insulin users 
identified similar attributes of major importance relating to 
insulin therapy. Based on the results of the qualitative study, 
published data, and consultation with diabetes educators and 
clinicians, the attributes identified and included in the DCE 
questionnaire were: fasting blood glucose control; weight 
gain in the first year (low [2 kg], moderate [6 kg], and high 
[10 kg]); route of administration for the long-acting insulin 
(oral and subcutaneous), administered once daily; route of 
administration for the short-acting insulin (oral, subcutane-
ous, and inhaled) administered 3 times daily; and monthly   
out-of-pocket cost (C$0, C$50, C$100, and C$200).
The attributes and levels defined in Table 1 gave rise to 
648 (21 × 34 × 41) possible combinations of treatment sce-
narios. Therefore, because the full factorial design of 648 
possible scenarios was not feasible, a fractional factorial 
design was used to reduce the number of scenarios to a more 
feasible number while still being able to estimate utilities for 
all combinations of attribute levels.
One strength of this design model is its ability to develop 
multiple versions of the questionnaire, which significantly 
increases the statistical efficiency of the study. Thus, 
6   fractional factorial designs optimizing D-efficiency (a sum-
mary measure of how precisely this design can estimate all 
parameters of interest with respect to another design) were 
generated to create a questionnaire with a feasible and prac-
tical number of choice sets Each version was designed to 
present each participant with the same number of scenarios, 
each with the same attributes, but the levels of all attributes 
in each questionnaire differed. D-efficiency summarizes how 
precisely this design can estimate all parameters of interest 
with respect to another design.
Based on 6 versions of the questionnaire each containing 
15 different choice sets, the sample size required for this 
study was estimated using Sawtooth® software, version 6.4.2 
(Sawtooth Software Inc., Sequim, WA, USA). 15 Based on 
this, we determined that the minimum sample size required 
was 130 respondents. Accounting for potential missing data 
and inconsistent responses, a target of 200 participants was 
selected. Using the CBC/Web module within Sawtooth, 
Table 1 sociodemographic and diabetes-related characteristics 
of participants (n = 274)
Characteristic Number (%) or   
mean (SD)
Mean age 56.7 (12.98)
Gender
  Male 144 (52.55)
  Female 130 (47.45)
Most recent hbA1c level
  4%–7% 103 (37.59)
  7.1%–10% 125 (45.62)
  .10% 24 (8.76)
  Do not know 18 (6.57)
number of hypoglycemic events (per month)a
  none 113 (41.24) 
  1–2 64 (23.36) 
  3–4 48 (17.52) 
  5–6 23 (8.39) 
  7–8 13 (4.74) 
  .8 9 (3.28)
Type of diabetes
  Type 1 47 (17.15) 
  Type 2 227 (82.85)
insulin statusb
  insulin users 134 (48.91) 
  insulin nonusers 139 (50.73) 
highest education level completed
  some high school 30 (10.95)
  completed high school 66 (24.09) 
  Trade/technical college 92 (33.58) 
  University 60 (21.89)
  Masters or doctorate degree 18 (6.57) 
Annual income by categories (c$):
  Low (,20,000) 33 (12.04) 
  Medium (20,001–50,000) 74 (27.01) 
  high ($50,001) 120 (43.80) 
Notes: a4 missing; b1 missing.
Abbreviation: sD, standard deviation.Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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6 different orthogonal designs of 15 choice sets with 2 
treatment options each were created. In addition, the validity 
of responses was assessed by including 2 fixed choice sets in 
each version in which 1 treatment option was clearly   “better”, 
ie, dominant, and thus should be the preferred treatment. 
Respondents were expected to choose the dominant option 
if they understood the task; those who “failed” both tests 
were defined as “inconsistent” (lack of understanding of the 
questionnaire) and were excluded from the final analysis. 
Because these fixed scenarios did not require respondents 
to make any trade-offs, they were not included in the final 
analysis.
statistical procedures
Descriptive statistics were performed using the SAS statisti-
cal software package, version 9.1 (SAS Institute, Cary, NC).16 
DCE analysis was performed using both Sawtooth® and the 
SAS statistical software packages. Random utility theory is 
used to model DCEs.17
Response data were analyzed using conditional logit 
regression. First, a full model including all consistent respon-
dents was developed that allowed for the determination of 
the overall or mean preferences of the sample. In addition, 
segmented models were used to evaluate whether patients’ 
preferences differed between subgroups (eg, insulin user 
or insulin naïve, type 1 or type 2 diabetes). Z-tests were 
performed to test for significant differences (P # 0.05) in 
preferences between the predefined subgroups.
The individual regression coefficients represent the 
average relative utility, or preference, for that level of that 
attribute. Both the sign and the magnitude of the regression 
coefficient for a specific attribute level reveal information 
about the average relative preference for that level of that 
attribute in the sample. Specifically, a positive regression 
coefficient suggests that patients prefer more of that attribute 
(ie, greater likelihood of benefit), whereas a negative coef-
ficient suggests that, on average, patients prefer to have less 
of that characteristic (eg, an adverse event).
For the discrete choice data in this study, effect-coded 
variables were created for each level of all attributes; how-
ever, as a linear relationship existed between the levels for 
the cost attribute, this variable was analyzed as a continuous 
variable.
Results
response rate and usable data
Of the 378 questionnaires distributed, 291 (77%) were 
returned. Of these, 7 returned incomplete questionnaires and 
10 “failed” both consistency choice sets and were excluded 
from the analysis. Therefore, 274 participants completed 
the questionnaire and were included in the final analysis. 
Questionnaires versions 1, 2, 3, 4, 5 and 6 were completed 
by 44, 50, 48, 45, 47, and 43 patients, respectively.
sample characteristics
Detailed information regarding socioeconomic and diabetes-
related factors of the study participants is presented in 
Table 1. The mean age (SD) of participants was 56.7 (12.9) 
years, and 53% were men. Two hundred twenty-seven (83%) 
participants had type 2 diabetes and 134 (49%) were insulin 
users. Forty-four percent of participants had an annual house 
income of .C$50,000.
conditional logit model
The results of the conditional logit model analysis conform to 
a priori postulated model predictions, validating the theoreti-
cal construct of the model. All regression coefficients were 
statistically significantly associated with treatment choices 
(P , 0.05), except for 4 hypoglycemic events per month 
compared to none (P = 0.0532), and inhaled as the route of 
administration for the short-acting insulin. Estimated coef-
ficients, standard errors, and P values for the estimated utility 
equation are shown in Table 2.
Overall, in descending order of importance, patients’ ideal 
insulin treatment would result in better glucose control, fewer 
hypoglycemic events, be less costly, and both long and short-
acting insulin would be administered orally. Participants in 
this sample showed a strong preference for better glucose 
control relative to the other attributes investigated. However, 
in their preferred route of delivery, patients showed a stronger 
preference for oral administration of the short-acting insulin 
over both inhaled (P , 0.001) and subcutaneous insulin 
(P , 0.001), and they also preferred inhaled over subcutane-
ous administration (P , 0.001). For the long-acting insulin, 
patients also preferred oral administration to subcutaneous 
(P , 0.001).
segmented models
Stratification of the sample by insulin use revealed that 
insulin users preferred oral short-acting insulin to inhaled 
(P = 0.006); however, insignificant differences were observed 
between oral and subcutaneous (P = 0.192), as well as 
between inhaled and subcutaneous (P = 0.167). Conversely, 
insulin-naïve patients preferred both oral and inhaled short-
acting insulin over subcutaneous (P , 0.001), but there was 
no statistically significant difference in their preferences for Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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oral or inhaled insulin (P = 0.064). For long-acting insulin, 
they preferred oral to subcutaneous (P , 0.001).   Comparing 
preferences of insulin users versus naïve revealed that insulin-
naïve patients had a stronger positive preference for oral 
long-acting (P , 0.001) and short-acting insulin relative to 
insulin users (Table 3). They also had a stronger preference 
for inhaled insulin compared to insulin users (P , 0.001). In 
addition, insulin users had a stronger preference for a treat-
ment that would not result in any hypoglycemic events per 
month (P = 0.012) compared to insulin-naïve participants.
Stratification of the sample by type of diabetes revealed 
that although patients with type 1 diabetes had stronger posi-
tive preferences for both oral and subcutaneous short-acting 
insulin relative to inhaled, the differences in preference 
between these 3 routes were not statistically significant. 
  Similarly, there was an insignificant difference in their 
preference for oral and subcutaneous long-acting insulin 
(P = 0.083). On the other hand, patients with type 2 dia-
betes preferred oral short-acting insulin over both inhaled 
(P = 0.001) and subcutaneous insulin (P , 0.001). They 
also preferred inhaled insulin over subcutaneous (P = 0.001). 
Similarly, they preferred an oral long-acting insulin over 
subcutaneous (P , 0.001). The comparison of patients with 
type 1 or type 2 diabetes revealed that patients with type 2 
diabetes had a stronger preference for the oral route for the 
long-acting insulin (P = 0.008) (Table 4); however, for the 
short-acting insulin, although patients with type 2 diabetes 
had a greater preference for an inhaled and an oral insulin 
than did patients with type 1 diabetes, these differences 
were not statistically significant. In addition, patients with 
type 1 diabetes had a stronger preference for subcutaneous 
short-acting insulin relative to patients with type 2 diabetes 
(P = 0.003). For glucose control, patients with type 1 diabetes 
had a stronger positive preference for optimal (P , 0.001) 
and suboptimal (P = 0.034) control, and a stronger negative 
preference for poor control (P , 0.001).
Discussion and conclusions
Findings from the present study revealed that patients’ 
ideal insulin treatment would provide better glucose con-
trol, result in fewer adverse events, have the lowest cost, 
and be administered orally. Moreover, there was a strong 
positive preference for better glucose control relative to the 
other attributes, while route of insulin administration was 
not as important as hypothesized a priori. Stratification of 
the sample by insulin use and type of diabetes revealed a 
strong negative preference for the subcutaneous insulin by 
insulin-naïve participants and those with type 2 diabetes, 
while patients with type 1 diabetes and insulin users had 
stronger positive preference for increased control and fewer 
adverse events compared with patients with type 2 diabetes 
and the insulin naïve.
It has been argued that improved diabetes outcomes 
may be achieved by combining psychosocial support with 
appropriate medical care.18 Greater involvement of patients 
in making decisions about their medication has been advo-
cated and the importance of medication concordance (agree-
ment between the patient and the health care provider that 
addresses patients’ preferences and concerns about whether, 
when, and how medication is to be taken) has been recog-
nized in the literature.19,20 Building concordant patient–health 
care provider relationships may depend on health care pro-
viders developing strategies to address patients’ preferences 
for involvement in the treatment decision-making process.21 
In this context, the results of the present study add to the 
current literature as a formal valuation and quantification of 
patients’ preferences for insulin therapy, and how they may 
be willing to trade off different attributes of insulin therapy, 
including route of insulin delivery, for better control or poten-
tially fewer adverse events. However, these results merely 
provide average preferences over the sample. Therefore, it 
is essential that an individuals’ preferences be explored and 
considered when making treatment decisions.
Table  2  relative  preferences  –  full  conditional  logit  model   
(n = 274)a
Treatment 
attributes
Regression 
coefficient (SE)b
Fasting blood glucose control
  Optimal
  suboptimal
  Poor
0.581 (0.032)
0.121 (0.027)
–0.702 (0.034)
number of hypoglycemia events per month
  none
 4
 8
0.243 (0.030)
0.053 (0.027)d
–0.296 (0.031)
Weight gain in the first year
  Low (2 kg)
  Moderate (6 kg)
  high (10 kg)
0.272 (0.030)
0.143 (0.028)
–0.416 (0.031)
route of administration for the long-acting insulin
  Oral
  subcutaneous
0.054 (0.017)
–0.054 (0.017)c
route of administration for the short-acting insulin
  subcutaneous
  inhaled
  Oral
cost
–0.171 (0.031)
0.014 (0.029)e
0.156 (0.028)
–0.004 (0.000)
Notes: aLog likelihood function: -2484; McFadden’s log-likelihood ratio: 0.123; bse: 
standard error;  bP , 0.001, except as noted;  cP = 0.002;  dP = 0.053;  eP = 0.612 
Abbreviation: se, standard error.Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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Table 3 relative preferences – segmented model: insulin users vs insulin naïve
Treatment attributes Insulin users Insulin naïve z-test 
(users × naïve)
Regression coefficient (SE) Regression coefficient (SE) P value
Fasting glucose control
  Optimal
  suboptimal
  Poor
0.662 (0.049)
0.109 (0.039)
–0.772 (0.052)
0.535 (0.045)
0.135 (0.038)
–0.670 (0.048)
0.055
0.635
0.151
number of hypoglycemia events per month
  none
 4
 8
0.341 (0.047)
0.031 (0.039)
–0.372 (0.047) 
0.183 (0.042)
0.067 (0.039)
–0.250 (0.044)
0.012
0.518
0.057
Weight gain in the first year
  Low (2 kg)
  Moderate (6 kg)
  high (10 kg)
0.316 (0.044)
0.170 (0.041)
–0.486 (0.047)
0.249 (0.043)
0.130 (0.039)
–0.380 (0.042)
0.278
0.479
0.092
route of administration for the long-acting insulin
  Oral
  subcutaneous
–0.042 (0.025)
0.041 (0.025)
0.146 (0.024)
–0.146 (0.024)
,0.001
,0.001
route of administration for the short-acting insulin
  subcutaneous
  inhaled
  Oral
cost
0.002 (0.044)
–0.083 (0.042)
0.081 (0.042)
–0.004 (0.000)
–0.344 (0.045)
0.119 (0.041)
0.225 (0.040)
–0.005 (0.000)
,0.001
,0.001
0.013
0.918
Abbreviation: se, standard error.
Table 4 relative preferences – segmented model: type 1 vs type 2 diabetes
Treatment attributes Type 1 diabetes Type 2 diabetes z-test 
(type 1 × type 2)
Regression coefficient (SE) Regression coefficient (SE) P value 
Fasting glucose control
  Optimal
  suboptimal
  Poor
0.937 (0.095)
0.262 (0.070)
–1.199 (0.105)
0.527 (0.035)
0.100 (0.029)
–0.627 (0.037)
,0.001
0.034 
,0.001 
number of hypoglycemia events per month
  none
 4
 8
0.409 (0.088)
–0.046 (0.072)
–0.363 (0.088)
0.226 (0.033)
0.066 (0.030)
–0.291 (0.034)
0.051
0.154
0.449
Weight gain in the first year
  Low (2 kg)
  Moderate (6 kg)
  high (10 kg)
0.340 (0.084)
0.20 (0.076)
–0.537 (0.091)
0.269 (0.033)
0.142 (0.030)
–0.412 (0.033)
0.438
0.505
0.195
route of administration for the long-acting insulin
  Oral
  subcutaneous
–0.057 (0.046)
0.057 (0.046)
0.075 (0.019)
–0.075 (0.019)
0.008 
0.008 
route of administration for the short-acting insulin
  subcutaneous
  inhaled
  Oral
cost
0.041 (0.082)
–0.097 (0.078)
0.056 (0.077)
–0.003 (0.000)
–0.219 (0.034)
0.037 (0.032)
0.182 (0.031)
–0.005 (0.000)
0.003 
0.109
0.131
0.269
Abbreviation: se, standard error.
No previously published studies in this area22,23 included 
an oral route for insulin administration or weight-gain in their 
evaluation. Oral insulins have been extensively investigated 
and are on the horizon, and weight gain was commonly 
raised during the focus group sessions as one of the most 
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excluding these attributes from decision making will reduce 
the degree to which the simulated decision process can 
applied in the real world. Furthermore, we have also evalu-
ated patients’ willingness-to-pay to avoid weight gain related 
to insulin therapy, and we found out that this adverse event 
was the second most valued attribute in the study.24
Undertaking stratified analyses was key, in that it revealed 
differences in preferences between different types of patients 
which could not be observed within the full model. We 
showed that patients with type 1 diabetes, and insulin users, 
had a stronger preference for better glucose control and avoid-
ance of adverse events compared with type 2 diabetics and 
insulin-naïve participants, respectively. However, differences 
in preferences for alternative routes of insulin administration 
revealed particularly interesting findings. Although previous 
studies have shown a stronger preference for inhaled over 
subcutaneous insulin by patients with type 1 diabetes,25,26 and 
higher willingness-to-pay for inhaled insulin for those who 
were dissatisfied with their current insulin therapy, the pres-
ent study revealed different findings. Specifically, patients 
with type 1 diabetes were indifferent to the route of insulin 
administration, while those with type 2 diabetes preferred 
oral long- and short-acting insulin. Moreover, insulin-naïve 
participants had a stronger positive preference for both 
inhaled and oral short-acting insulin and for an oral long-
acting insulin relative to insulin users. Therefore, findings 
from the stratification of the sample by insulin use and type 
of diabetes suggest that there may be an important barrier to 
initiating therapy with subcutaneous insulin, but that patients 
tend to accommodate and accept the subcutaneous route once 
they start using insulin. Once the initial barriers to insulin use 
are overcome and treatment is implemented, other aspects of 
treatment then become more important.
The study findings can be used to guide future directions 
for drug development, with a focus on increasing the abil-
ity to improve glucose control and reduce adverse events. 
Moreover, one explanation for the low valuation patients 
placed on route of insulin administration may be the fact 
that insulin users and patients with type 1 diabetes were 
more likely to have experienced at least 1 serious adverse 
event (ie, hypoglycemia), and therefore they may be more 
concerned about avoiding these adverse events than with 
the route of insulin delivery. A second explanation is that, 
as mentioned earlier, patients tend to adjust to subcutaneous 
administration once they start using insulin. These findings 
are of great importance since they may be important in help-
ing understand patients’ decisions about initiation of various 
insulin treatment strategies.
This study found that patients were capable of understanding 
and making decisions based on complex information. The 
findings also demonstrate that the present study was capable 
of evaluating and quantifying patients’ preferences for insulin 
therapy, which may provide diabetes educators with useful 
information for the development of targeted diabetes educa-
tion and individualized treatment approaches, allowing them 
to help select management plans more aligned with patients’ 
preferences. Furthermore, findings from the stratification of 
the sample suggest that efforts need to be made to overcome 
the barriers to initiating insulin therapy, which may lead to 
improved control, through improved treatment acceptance, 
and ultimately reduce the financial burden of the disease and 
improve patients’ quality of life.
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